Company: PRGO
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001585364-25-000156
Chunk: 86

Company: PERRIGO Co plc
Filing Date: 2025-11-05
Form: 10-Q
Item: Part II, Item 1
Chunk 86
---
 Business and the Rare Diseases Business, decreased restructuring costs of $39.2 million driven by Project Energize and a decrease in Other operating (income) expense, net due to lower litigation expenses partially offset by the absence of the prior year gain on sale of branded products of $26.0 million.

CONSUMER SELF-CARE AMERICAS FINANCIAL RESULTS

Three Month Comparison

 Three Months Ended(in millions, except percentages)September 27, 2025September 28, 2024Net sales$645.6 $671.3 Gross profit$205.6 $219.4 Gross profit %31.8 %32.7 %Operating income$94.7 $102.2 Operating income %14.7 %15.2 %

Net sales decreased $25.7 million, or 3.8%, due primarily to:

•$25.6 million decrease, or 3.8%, due primarily to lower net sales in the Nutrition category of $27.3 million, driven by a strong product pipeline refill to contract manufacturing customers and consumer pantry loading ahead of a port strike threat in the prior year quarter and lost distribution of the Good Start® brand, and unfavorable impacts across multiple U.S. OTC businesses due to soft category consumption. These were partially offset by higher net sales in the Upper Respiratory category of $8.3 million, due primarily to new distribution and store brand share gains amid lower consumption, as well as higher net sales in the Skin Care category of $6.9 million due primarily to higher consumption within the Minoxidil franchise and new distribution in addition to higher net sales of Mederma®.

CSCA net sales by product category were as follows:

SalesThree Months Ended(in millions, except percentages)September 27, 2025September 28, 2024$ Change% ChangeUpper Respiratory$129.2 $120.9 $8.3 6.8 %Digestive Health105.5 113.5 (8.0)(7.0)%Nutrition99.8 127.1 (27.3)(21.5)%Pain and Sleep-Aids88.6 87.7 0.9 1.0 %Healthy Lifestyle77.5 80.9 (3.5)(4.3)%Oral Care62.8 66.9 (4.2